Columbia University spinout Foli Bio is developing exfoliated fecal RNA sequencing panels intended to predict drug response in inflammatory bowel disease (IBD) patients and potentially replace some surveillance endoscopies. The company plans stool‑based RNA assays to monitor mucosal biology noninvasively and guide therapy selection. Foli Bio’s approach seeks to capture host and microbial transcriptional signals shed in stool to infer intestinal inflammation and treatment responsiveness. The platform targets clinical decision points where a blood test or stool assay could reduce reliance on invasive scopes. If validated in prospective studies, fecal RNA panels could change monitoring workflows in gastroenterology and support precision prescribing in IBD.